4,5,6,7-tetrahydrobenzo[d]oxazole | 40814-50-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4,5,6,7-tetrahydrobenzo[d]oxazole
• 英文别名: 4,5,6,7-tetrahydrobenzoxazole；4,5,6,7-tetrahydro-benzooxazole；4,5,6,7-tetrahydro-benzoxazole；4,5,6,7-Tetrahydro-benzoxazol；4,5,6,7-Tetrahydrobenzoxazol；4,5-Tetramethylen-oxazol；4,5,6,7-Tetrahydro-1,3-benzoxazole
• CAS: 40814-50-4
• 化学式: C₇H₉NO
• 分子量: 123.155
• InChiKey: ICZQPMMRUBWVAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4,5,6,7-tetrahydrobenzo[d]oxazole 在 氧气 、 亚甲兰 作用下， 以 二氯甲烷 为溶剂， 生成 (ω-Cyan-valeriansaeure)-ameisensaeureanhydrid
  参考文献：
  名称：

  The reaction of oxazoles with singlet oxygen. II. A novel method for the preparation of .omega.-cyano acids

  摘要：

  DOI：

  10.1021/ja01011a053
• 作为产物：
  描述：

  2-甲酰基氨基-环己酮 生成 4,5,6,7-tetrahydrobenzo[d]oxazole
  参考文献：
  名称：

  Mechanistic studies on the photochemical reactions of isoxazoles

  摘要：

  DOI：

  10.1021/jo00863a003

文献信息

• New 4-arylpiperidine derivatives for the treatment of pruritus
  申请人：——

  公开号：US20030004340A1

  公开（公告）日：2003-01-02

  There is provided a compound of formula I, 1 wherein Het 1 , R 1 , R 2 , R 3 , X and n have meanings given in the description, which are useful in the prophylaxis and in the treatment of diseases mediated by opiate receptors, such as pruritus.

  提供了一种公式I的化合物，其中Het1、R1、R2、R3、X和n具有说明书中给出的含义，它们在通过阿片受体介导的疾病的预防和治疗中是有用的，例如瘙痒。
• [EN] 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS<br/>[FR] DERIVES CYCLOALKYLES 1,1-DISUBSTITUES UTILISES EN TANT QU'INHIBITEURS DU FACTEUR XA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003099276A1

  公开（公告）日：2003-12-04

  The present application describes 1,1-disubstituted cycloalkyl compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

  本申请描述了1,1-二取代环烷基化合物及其衍生物，或其药用可接受的盐形式，这些化合物对于Xa因子的抑制剂具有用处。
• Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150307465A1

  公开（公告）日：2015-10-29

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, -L 2 -, and -L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

  本发明提供了多种形式的亚氨基噻二唑二氧化物化合物，包括公式(I)的化合物： 包括它们的立体异构体，以及所述立体异构体的药用可接受盐，其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、-L2-和-L3-都是独立选择且按本文定义。发明的新型亚氨基噻二唑二氧化物化合物出人意料地被发现具有预期的特性，使其作为BACE抑制剂以及/或用于治疗和预防与β-淀粉样蛋白（“Aβ”）生成相关的各种病理学具有优势。还公开了包含一个或多个此类化合物（单独使用和与一个或多个其他活性成分组合使用）的药物组合物，以及它们的制备方法和用于治疗与淀粉样β（Aβ）蛋白相关的病理学，包括阿尔茨海默病的方法。
• [EN] ACETAMIDE COMPOUNDS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION<br/>[FR] COMPOSÉS D'ACÉTAMIDE, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR APPLICATION PHARMACEUTIQUE
  申请人：ADVINUS THERAPEUTICS LTD

  公开号：WO2012020357A1

  公开（公告）日：2012-02-16

  This disclosure relates to a series of acetamide compounds of formula (I), their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof. The disclosure also relates to process of preparation of the acetamide compounds. The compounds of the present disclosure are identified as Glucokinase activators or modulators.

  这份披露涉及到一系列的乙酰胺化合物，其化学式为(I)，它们的立体异构体、互变异构体、前药、药用可接受盐、多型体、溶剂合物以及配方。该披露还涉及到制备乙酰胺化合物的方法。本披露的化合物被确定为葡萄糖激酶激活剂或调节剂。
• New Piperazine Compound and Use Thereof as a HCV Polymerase Inhibitor
  申请人：Abe Hiroyuki

  公开号：US20080081818A1

  公开（公告）日：2008-04-03

  The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]表示的化合物，其中每个符号如规范中定义，或其药学上可接受的盐，或其溶剂化合物，以及含有该化合物的抗HCV剂和HCV聚合酶抑制剂。本发明的化合物基于HCV聚合酶抑制活性显示出抗HCV活性，并且可用作预防或治疗丙型肝炎的药剂。